662PBiomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). (23rd October 2018) - Catenacci, D V T; Park, H; Uronis, H E; Kang, Y-K; Ng, M; Gold, P; Lacy, J; Enzinger, P C; Park, S; Lee, K-W; Yen, J; Odegaard, J; et al.